Accendra Health reported first-quarter results that exceeded consensus estimates, triggering a notable uptick in its stock price. Revenue growth and improved profitability metrics underpinned investor confidence despite limited disclosure of exact figures.

The company unveiled a comprehensive balance sheet optimization deal aimed at bolstering liquidity and reducing overall leverage. The transaction is expected to involve debt refinancing and potential asset sales to lower funding costs and extend maturities.